Author Affiliation: Genetic Epidemiology Unit, King's College London, St Thomas' Hospital, London, England.
De Giorgi et al1 reported that use of β-blockers is associated with a reduced risk of melanoma progression. This observation is important because in recent years various novel roles of β-blockers have been introduced. A great example is the successful use of the nonselective β-blocker propranolol, which revolutionized the treatment of infantile hemangioma. Thus, there is a need to further explore the potential therapeutic role of β-blockers in melanoma.
Lens M. Do β-Blockers Slow Down Melanoma Progression?. Arch Intern Med. 2011;171(18):1686-1687. doi:10.1001/archinternmed.2011.483